Rising Vaccine Courses Powering Growth In The Rotavirus Prophylaxis Market: A Key Catalyst Accelerating Rotavirus Prophylaxis Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Rotavirus Prophylaxis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The size of the market for rotavirus prophylaxis has seen a swift expansion in the recent past. It is projected to expand from a value of $9.05 billion in 2024 to reach $10.03 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.8%. The aforementioned growth during the historic phase could be credited to factors such as access and fairness of vaccines, the emergence of new rotavirus strains, investments in research and development, as well as readiness in public health.

Rotavirus Prophylaxis Market Size Forecast: What's the Projected Valuation by 2029?
The market for rotavirus prophylaxis is anticipated to witness robust expansion in the upcoming years and is projected to achieve a market worth of $14.63 billion in 2029, expanding at a compound annual growth rate (CAGR) of 9.9%. The growth predicted in this period is primarily due to factors such as the burden of gastrointestinal diseases, global scaling-up efforts, immunization initiatives, and trust in vaccines. Key trends to watch out in this time frame encompass next-gen vaccines, combination vaccines, innovative delivery methods for vaccines, and worldwide immunization partnerships.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report

What Are the Drivers Transforming the Rotavirus Prophylaxis Market?
The growth of the rotavirus prophylaxis market is set to be propelled by the rise in vaccine courses. Essentially, a vaccine course is a particular dosage of a vaccine provided to an individual to provide immunity against a specific disease. This dosage boosts the immune response, offering excellent defense against rotavirus infections. The heightened immunity reduces disease risk, enhancing the overall effectiveness of the vaccine. For instance, a report by the United Nations International Children's Emergency Fund (UNICEF), a US humanitarian and developmental assistance provider for children, showed about 5.71 million courses of the RV1-5 frozen rotavirus vaccine was produced in January 2022, with a estimated increase to 9.31 million courses by 2028. Additionally, around 5.29 million courses of the lyophilized RV5-2 rotavirus vaccines were made in 2022, projected to rise to 6.13 million courses by 2028. Thus, these increasing vaccine amounts will boost rotavirus prophylaxis market growth. The anticipated growth of the rotavirus prophylaxis market will also be driven by institutional funding. Institutional funding is the allocation of resources, such as money, effort or time, to cater to a requirement, program or project. The rise in cases of rotavirus has garnered the attention of both government and private organizations for funding. This financial and technical assistance promotes the development phases of rotavirus vaccines and oral treatments. For example, Indiana University, a public research institution in the US, was granted a $1.2 million fund by venture capital firm, GIVAX Inc. in April 2022. The funding was aimed at creating a new technology for a combined oral rotavirus-norovirus vaccine for infants. This innovative technology broadens the rotavirus vaccine's reach to include protection against the highly contagious norovirus, notorious for causing severe vomiting and diarrhea in young children. Therefore, the increased availability of this funding is expected to significantly boost the rotavirus prophylaxis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp

What Long-Term Trends Will Define the Future of the Rotavirus Prophylaxis Market?
Leading firms in the rotavirus prophylaxis industry are working on vaccines that cater to the needs of their customers. The vaccine approval process is stringent and includes several stages of development and testing. Such approvals ensure the vaccines' safety and effectiveness in preventing this viral disease, especially among infants and young children. For instance, GlaxoSmithKline PLC, an established pharmaceutical and biotechnology company from the UK, revealed in November 2022 that the FDA approved their ROTARIX (Rotavirus Vaccine, Live and Oral) in a novel all-liquid, oral-dosing applicator-only presentation that guards against rotavirus gastroenteritis triggerred by G1 and non-G1 types (G3, G4, and G9) in infants. This new format is entirely liquid and requires no reconstitution prior to use. Both the lyophilized and liquid ROTARIX formulations are orally administered in a two-dose cycle, contain the same live, human-attenuated rotavirus strain, and are produced using similar methods.

Which Segments in the Rotavirus Prophylaxis Market Offer the Most Profit Potential?
The rotavirus prophylaxis market covered in this report is segmented -

1) By Treatment: Rotarix, Rotavac, Rotavin-M1, Oral Rehydration Fluid, Other Treatments
2) By Route of Administration: Oral, Parenteral, Other Route of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Rotarix: Single Dose, Multi-Dose
2) By Rotavac: Liquid Formulation, Freeze-Dried Formulation
3) By Rotavin-M1: Liquid Formulation, Freeze-Dried Formulation
4) By Oral Rehydration Fluid: Electrolyte Solutions, Glucose-Based Solutions
5) By Other Treatments: Supportive Care, Antidiarrheal Medications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13045&type=smp

Which Firms Dominate the Rotavirus Prophylaxis Market by Market Share and Revenue in 2025?
Major companies operating in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).

Which Regions Offer the Highest Growth Potential in the Rotavirus Prophylaxis Market?
North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13045

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.